Study of Early Cancer Biomarkers in Breath Condensate in Population of Individuals With High-Risk of Lung Cancer Undergoing LDCT Screening.
Recruiting · NCT06016569 · Interventional (participants receive a specific treatment) · Lead sponsor: The Institute of Molecular and Translational Medicine, Czech Republic
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
The trial will evaluate if the newly identified biomarkers of lung cancer in exhaled breath condensate are as a diagnostic tool comparable to the low-dose computer tomography (LDCT) implemented in lung cancer screening recently. Due to the possibility to collect breath condensate at any medical workplace and due to the relatively low financial cost of examination of the collected breath condensate could improve early diagnosis of lung cancer, differential diagnostics of lung nodules and thereby reduce both the unnecessary interventions and deaths from this type of cancer.
Who can take part
Inclusion criteria
- Consent to participate in a clinical trial.
- A clients within an age of 55-74 years.
- Current smoker or ex-smoker who has smoked at least 20 pack-years, provided that:
- priority will be given to clients who have smoked at least 30 pack-years.
- preference will be given to a former smoker who has not smoked for less than 15 years.
Exclusion criteria
- Previous diagnosis of lung cancer.
- Progressing malignant tumor on symptomatic treatment.
- Advanced dementia
- Chronic obstructive pulmonary disease or other inflammatory disease in the phase of acute exacerbation.
Where it is running
3 locations listed.
- Masaryk Memorial Cancer Institute - Brno, Czechia
- University Hospital - Olomouc, Czechia
- General University Hospital in Prague - Prague, Czechia